Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03729609 Completed - Clinical trials for Untreated CD30-Positive Hodgkin's Lymphoma

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Start date: November 1, 2018
Phase:
Study type: Observational

The purpose of this survey is to monitor and identify the occurrence of neutropenia and febrile neutropenia in untreated CD30-positive Hodgkin's lymphoma participants on concomitant brentuximab vedotin and doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) in routine clinical practice.

NCT ID: NCT03728972 Active, not recruiting - Clinical trials for NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Start date: November 9, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.

NCT ID: NCT03722186 Suspended - Lymphoma Clinical Trials

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Start date: November 13, 2018
Phase: Phase 1
Study type: Interventional

SHR-1603-I-101 is an single-arm, open-label, dose finding phase I clinical trial of SHR-1603 in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases. The study drug will be administered by intravenous infusion.

NCT ID: NCT03722147 Completed - Hodgkin's Lymphoma Clinical Trials

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

Start date: August 13, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, open-label, multicenter, phase I/II study to evaluate efficacy and safety of AK105 in patients with relapsed or refractory classic Hodgkin lymphoma.

NCT ID: NCT03720496 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T, an autologous tri-functional anti- CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in Refractory/ Relapsed CD19 Positive Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT03720457 Recruiting - Follicular Lymphoma Clinical Trials

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Start date: November 13, 2018
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.

NCT ID: NCT03719989 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EPIC
Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

This phase II clinical trial aims at evaluating the efficacy and safety of azacitidine followed by rituximab-GDP immunochemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients who were treated with from 1 to 4 lines of prior therapies for relapsed/refractory DLBCL wee eligible. azacitidine will be treated one week prior to conventional rituximab-gemcitabine, dexamethasone, cisplatin (R-GDP) immunochemotherapy. Patients will be treated every 21 days as one cycle, and up to 6 cycles. The primary endpoint of this study is objective response rate according to the Lugano response criteria for non-Hodgkin lymphoma, and secondary endpoints are safety, complete response, progression-free survival, and overall survival.

NCT ID: NCT03719898 Withdrawn - Clinical trials for Anaplastic Large Cell Lymphoma, ALK-Positive

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Start date: December 6, 2018
Phase: Phase 2
Study type: Interventional

FDA approved drugs to treat patients with relapsed or refractory anaplastic large cell lymphoma (ALCL) has a median progression free survival of 20 months. Majority of patients relapse in 2 years. This study will evaluate overall response rate of next generation ALK inhibitor brigatinib in ALK positive ALCL patients by overcoming mechanisms of resistance to ALK inhibitors on cancer patients.

NCT ID: NCT03719560 Withdrawn - Clinical trials for Diffuse Large B Cell Lymphoma

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

BrUOG-377
Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

Phase 2 single-institution trial of early systemic central nervous system prophylaxis in high-risk diffuse large B-cell lymphoma

NCT ID: NCT03719105 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Start date: March 1, 2019
Phase: Early Phase 1
Study type: Interventional

Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) . Both groups proceed to allogeneic stem cell transplant with disease response.